Congratulations to the Skyhawk Therapeutics team on achieving a major clinical milestone in Huntington’s disease. These early results highlight meaningful progress toward potential new treatments for patients facing this devastating condition.
Excited to share our first interim data in our Phase 1 for Huntington's patients, showing 62% lowering of mutant huntingtin protein ~ check out the release here! https://lnkd.in/erVfdjcS
